Evidence map›Paper›PMID 25729743›Full record

ArticleEuropean journal of neurodegenerative disease

Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: regeneration and beyond.

Sarah E Latchney, Amelia J Eisch

Open access · greenAbstract read
In one paragraph

Article in European journal of neurodegenerative disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sarah E LatchneyDepartment of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 74309-9070, USA.
Amelia J EischDepartment of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Blvd. Dallas, TX 74309-9070, USA.
Southwestern Medical Center · US

Funding

Basic Science Training Program in Drug Abuse ResearchT32DA007290 · NIDA · YALE UNIVERSITY · PI SELF, DAVID W · 1992 to 2017
$6.7M
Regulation of adult neurogenesis by opiatesR01DA016765 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI EISCH, AMELIA J · 2004 to 2013
$4.0M
New Horizons in Adult NeurogenesisK02DA023555 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI EISCH, AMELIA J · 2007 to 2017
$1.1M
NIDA NIH HHS K02 DA023555NIDA NIH HHS R01 DA016765NIDA NIH HHS T32 DA007290
6 · The paper itself

Abstract

With the growth of the aging population and increasing life expectancy, the diagnosis of age-related neurodegenerative diseases is predicted to increase 12% by 2030. There is urgent need to develop better and novel treatments for disorders like Alzheimer's, Huntington's, and Parkinson's diseases. As these neurodegenerative diseases are customarily defined by the progressive loss of neurons, treatment strategies have traditionally focused on replacing neurons lost during disease progression. To this end, the self-renewing and multipotent properties of neural stem/precursor cells (NSPCs) that exist in the adult brain suggest that NSPCs could contribute to a therapy for replacement of damaged or lost neurons. Although a wealth of research demonstrates the proof-of-concept that NSPC transplantation has therapeutic potential, there are considerable barriers between the theory of cell transplantation and clinical implementation. However, a new view on harnessing the power of NSPC for treatment of neurodegenerative disorders has emerged, and focuses on treating neuropathological aspects of the disease prior to the appearance of overt neuronal loss. For example, rather than merely replacing lost neurons, NSPCs are now being considered for their ability to provide trophic support. Here we review the evolution of how the field has considered application of NSPCs for treatment of neurodegeneration disorders. We discuss the challenges posed by the "traditional" view of neurodegeneration - overt cell loss - for utilization of NSPCs for treatment of these disorders. We also review the emergence of an alternative strategy that involves fine-tuning the neurogenic capacity of existing adult NSPCs so that they are engineered to address disease-specific pathologies at specific time points during the trajectory of disease. We conclude with our opinion that for this strategy to become a translational reality, it requires a thorough understanding of NSPCs, the dynamic process of adult neurogenesis, and a better understanding of the pathological trajectory of each neurodegenerative disease.

Indexed as

hippocampusneurodegenerationsubgranular zonesubventricular zone

Identifiers

PMID25729743
PMCPMC4340249
OpenAlexW2177296786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.